Novel patient-derived myxofibrosarcoma cell lines as platforms for preclinical drug testing and near-patient model development (ESMO 2026) - Jul 17, 2026 - Abstract #422P; Pres time: Oct 23, 2026; 03:15 PM - 04:00 PM; Location: Poster Area - Hall 5; "Sensitivity to doxorubicin and palifosfamide was tested in 2D cultures, while 3D scaffolds were used to reproduce tumor architecture.Results We enrolled 7 pts and successfully established 3 stable pts-derived MFS cell lines that express HLA class I. TME analysis revealed CD45+ immune cells (38 ± 25%) infiltration enriched in exhausted central (CM) and effector memory (EM) CD4+ and CD8+ T cells expressing PD-1 (CD4+: CM: 76.8 ± 3.6%, EM: 95.4 ± 0.55%; CD8+: CM: 77 ± 11%, EM: 89.4 ± 1.13%), and TIM-3 (CD4+: CM: 36 ± 30%, EM: 51 ± 6%; CD8+: CM: 56 ± 14%, EM: 66 ± 10%). Drug sensitivity assays showed responsiveness to chemotherapy.Conclusions This exploratory study provides an initial molecular and immunological characterization of MFS and establishes novel patient-derived preclinical models. These findings support the development of biology-driven therapeutic strategies integrating..."
Preclinical • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • CD8 • HAVCR2 • IFNG • LAG3 • PD-1 • PD-L1 • PTPRC • TP53
|
|
Massimiliano Grassi; Cecilia Profumo; Valentina Rigo; Matteo Mascherini; Danila Comandini; Giorgia Arcovito; Giorgia Anselmi; Laura Damele; Paolo Nozza; Paola Ghiorzo; Lorenza Pastorino; Bruna S. Dalmasso; Alessandro De Vita; Silvia Vanni; Sara Violani; Simona Coco; Francesco Grossi; Paola Monti; Michela Croce
|